Clinical Trials Using Imiquimod

Clinical trials are research studies that involve people. The clinical trials on this list are studying Imiquimod. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-11 of 11
  • Topical or Ablative Treatment in Preventing Anal Cancer in Patients with HIV and Anal High-Grade Squamous Intraepithelial Lesions

    This randomized phase III trial compares topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. It is not yet known if treating HSIL is more effective than active monitoring in preventing patients from developing anal cancer.
    Location: 31 locations

  • Imiquimod, Fluorouracil, or Observation in Treating Patients with High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive

    This phase III trial studies imiquimod or fluorouracil to see how well they work compared to observation in treating patients with high-grade anal squamous skin lesions who are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether imiquimod or fluorouracil is more effective than observation in treating high-grade anal squamous skin lesions.
    Location: 15 locations

  • A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

    The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, as well as Nivolumab / Ipilimumab for selected advanced solid tumors.
    Location: 3 locations

  • Focused Ultrasound Ablation and PD-1 Antibody Blockade for the Treatment of Advanced Solid Tumors

    This phase I trial studies the side effects of focused ultrasound ablation and how well it works with or without PD-1 antibody blockade (a type of immune infused therapy drug) in treating patients with solid tumors that has spread to other places in the body (advanced). PD-1 antibody blockade is a type of treatment that uses an antibody that has been created to bind to immune cells to enable them to fight off cancer more effectively. The Echopulse device is a computer driven system which guides a high intensity focused ultrasound beam (focused sound waves) to a targeted area of a tumor. Focused ultrasound ablation (FUSA) heats the targeted site which causes the cells to die. In addition to the focused ultrasound beam that can kill cells at its target, the Echopulse device also uses low energy ultrasound for imaging the tumor tissue and the tissue around the tumor to make sure that the focused ultrasound beam hit its target. Imiquimod is an immunomodulator, a drug that interacts with the immune system. Through boosting the immune system, imiquimod may help the body fight off cancer cells. The purpose of this trial is to figure out the safety and effectiveness of FUSA administration alone or with a PD-1 antibody and / or imiquimod.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Cryoimmunotherapy and Pembrolizumab for the Treatment of Locally Advanced Unresectable or Cutaneous Metastatic Breast Cancer

    This phase IB trial studies the side effect of cryoimmunotherapy (cryotherapy, GM-CSF, and imiquimod) with pembrolizumab for the treatment of breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable) or has spread to the skin (cutaneous metastatic). Cryotherapy is a procedure in which extremely cold liquid (liquid nitrogen) is used to freeze and destroy abnormal tissue. GM-CSF and imiquimod may help the immune system kill abnormal cells, including tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cryoimmunotherapy with pembrolizumab may work better in treating breast cancer that includes skin lesions.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Fluorouracil with or without Imiquimod for the Treatment of Squamous Cell Carcinoma of the Lower Extremities

    This phase I trial studies the side effects of fluorouracil with or without imiquimod in treating patients with squamous cell carcinoma of the lower extremities. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Imiquimod may activate the immune system by stimulating the immune response which recruits pathogen fighting cells. Giving fluorouracil together with imiquimod may eliminate the need for surgery by significantly shrinking and / or eliminating the tumor, thereby preventing surgical complications and improving post-treatment outcomes in patients with squamous cell carcinoma of the lower extremities.
    Location: UPMC-Saint Margaret, Pittsburgh, Pennsylvania

  • Imiquimod and Pembrolizumab in Treating Patients with Stage IIIB-IV Melanoma

    This pilot early phase I trial studies the side effects and how well imiquimod and pembrolizumab work in treating patients with stage IIIB-IV melanoma. Imiquimod may stimulate the immune system. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving imiquimod and pembrolizumab may work better at treating melanoma.
    Location: Mayo Clinic in Florida, Jacksonville, Florida

  • Imiquimod with or without 9-Valent HPV Vaccine in Treating Patients with High-Grade Pre-neoplastic Cervical Lesions

    This phase II trial studies how well imiquimod with or without 9-valent human papillomavirus (HPV) vaccine work in treating patients with high-grade pre-neoplastic cervical lesions. Imiquimod may help to improve patients' immune system. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. It is not yet known whether giving imiquimod with or without 9-valent HPV vaccine may work better in treating patients with cervical lesions.
    Location: Yale University, New Haven, Connecticut

  • Personalized Peptide Vaccine in Treating Patients with Advanced Pancreatic Cancer or Colorectal Cancer

    This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing or kill them.
    Location: M D Anderson Cancer Center, Houston, Texas

  • HLA-A2 Restricted Peptide Vaccine and Imiquimod in Treating Children with Recurrent Ependymoma

    This pilot phase I trial studies the side effects and to see how well human leukocyte antigen (HLA)-A2 restricted peptide vaccine and imiquimod work in treating children with ependymoma that has come back after a period of improvement. Vaccines made from HLA-A2 restricted tumor antigen peptides and imiquimod may help the body build an effective immune response to kill tumor cells.
    Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

  • Vaccine Therapy with or without Imiquimod in Treating Patients with High-Grade Cervical Intraepithelial Neoplasia

    This pilot phase I trial studies the side effects and best dose of giving vaccine therapy with or without imiquimod in treating patients with high-grade cervical intraepithelial neoplasia. Vaccines made from deoxyribonucleic acid (DNA) or a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop cancer cells from growing. Giving vaccine therapy together with imiquimod may be a better treatment for cervical intraepithelial neoplasia.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland